Supercharging Immunotherapy

fancy black and blue t-cell 3d scientific images immune system

We work to reprogram the immune system to more effectively combat cancer and infectious diseases. We do this by using a technology that “supercharges” the natural ability of the immune system to combat disease.

26 May 2020

Tune in to the webcast presentation on Wednesday, 3 June 2020 at 8:30 ET.

14 May 2020

The Company reports its financial results and corporate update for the first…

4 May 2020

HOOKIPA will release financial results for the Q1 2020 before the market opens…

21 Apr 2020

The paper concludes that HB-101 was well tolerated and induced CMV-specific…

19 Mar 2020

HOOKIPA reports its financial results and corporate update for the fourth…

10 Mar 2020

HOOKIPA will release fourth quarter and full year 2019 financial results…

all news

The source of HOOKIPA’s strength lies in our people and the skills and experience that they bring. We want to continue to grow fast as a company and nurture a respectful and diverse culture that encourages teamwork. Attracting and retaining the best people is essential to achieve this. Please get in touch with us to find out more about our career opportunities.

Supercharging Immunotherapy

Our Mission

News

HOOKIPA Pharma to Present at Jefferies Virtual Healthcare Conference

HOOKIPA Pharma Reports First Quarter 2020 Financial Results and Provides a…

HOOKIPA Pharma To Report First Quarter 2020 Financial Results on May 14, 2020

HOOKIPA Pharma Announces Publication of HB-101 Phase 1 Results in The Journal…

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and…

HOOKIPA Pharma To Report Fourth Quarter and Full Year 2019 Financial Results…

Our Pipeline

Careers